Denali Therapeutics Inc. Common Stock

DNLI XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

3.1B

Short interest (May 15)

8.8%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.25%

↓ 19.6%

Available Shares

900K

↓ 6.5%

Price Chart

Company Overview

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001714899

Asset Type: CS

Market Data

Market Cap: $3,071,033,410

Employees: 507

Status: Active

Short Interest

Current Borrow Fee 0.25%

Range: 0.25% - 0.27%

Available Shares 900K

Range: 800K - 900K

Recent Changes

Fee Change: ↑ 2.6%

Available Change: ↓ 11.9%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime